Chugai Seiyaku Kabushiki Kaisha

Other

Perseus Proteomics Inc.

F. Hoffmann-La Roche Ag

Genentech, Inc.

Jsr Corporation

Jsr Life Sciences Corporation

Aburatani, Hiroyuki

Toshihiko Ohtomo

Masayuki Tsuchiya

Hirotaka Ito

Yukio Ito

Hiroyuki Aburatani

Yoshitaka Hippo

Yasuo Koishihara

Masaaki Kosaka

Koichiro Ono

Hirokazu Taniguchi

Yasuko Kinoshita

Shogo Yamamoto

Shumpei Ishikawa

Yong Xin Chen

Shin-ichi Fukumoto

Mikiyoshi Saito

Ying Qiu Guo

Takahiro Shimamura

Akira Watanabe

Masahiro Arai

Hiroyuki Tsunoda

Koh Sato

Naohiro Yabuta

Kunihiro Matsumoto

Tetsuro Orita

Yasushi Yoshimura

Naoko Kamimura

Yasuhiro Sugamata

Takayoshi Tanaka

Masashi Fukayama

Yasuo Sugitani

Jun Amano

Ya-Chi Chen

Tetsuji Yamaguchi

Hideki Adachi

Atsuhiko Kato

Tsukasa Suzuki

Ruey-Min Lee

Mikiko Nakamura

Ryoichi Saitoh

Yoshinori Narita

Anton Belousov

Mika Endo

Gong Chen

Motoaki Mizuuchi

Bernhard Reis

Naoka Kamimura

Kenji Adachi

Oscar Puig

Motooki Ashihara

Shin-ichi Funahshi

Shin-ichi Funahashi

Seiki Wakui

Shin-Ichi Fukumoto

The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.

Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies

A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.

GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

The present invention provides a method for determining the efficacy of a GPC3-targeting therapeutic agent for a liver cancer patient and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a GPC3-targeting therapeutic agent is effective when the expression level of GPC3 per tumor cell is a predetermined value, and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective.

GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.

Method for assaying soluble GPC3 protein

A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that binds to ROBO1 as an active ingredient are disclosed. Further, a method for inducing cell damages in a ROBO1 expressing cell and a method for inhibiting the growth of a ROBO1 expressing cell by bringing a ROBO1 expressing cell into contact with an antibody that binds to ROBO1, are disclosed. Furthermore, a method for monitoring progression of hepatitis by detecting ROBO1 protein is disclosed.

Cancer diagnosis and treatment of cancer using anti-ROBO1 antibody

Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.

Gene overexpressed in cancer

Cancer diagnosis and treatment of cancer using anti-robo 1 antibody

The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.

Degraded TPO agonist antibody

Revealed are that the actions of inflammatory cytokine and the production of inflammatory cytokines such as IL-1 and TNF induced by an inflammatory stimulus as well as the production of other inflammatory cytokines such as IL-6 induced by the former class of inflammatory cytokines are all suppressed by inhibiting the signal transduction through TAK1.

Methods of screening compounds inhibiting signal transduction through inflammatory cytokines

The invention provides a reshaped human anti-HM 1.24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. This reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, and the reshaped human antibody of the present invention has a low antigenicity and can be used for medical treatment.

Reshaped human anti-HM 1.24 antibody

Methods for measuring transporter activity using budding baculoviruses that do not express endogenous transporters on their envelope have a low background level and can measure the target activity with a high sensitivity. Such methods can be used to measure functional changes due to transporter SNPs over a more extensive range of substrates, and can be applied to tailor-made therapies.

Expressing transporters on viral envelopes

Growing community of inventors

Shizuoka, Japan

Toshihiko Ohtomo